SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

XARELTO

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercialized, U.S. market since 2011 (tablets) and 2021 (oral suspension); no pending approval timeline.
Why 3/10
No hard, dated binary catalyst in the next ~12 months: XARELTO is already approved and marketed (tablets since 2011, oral suspension NDA 215859 since 2021-12-20), and its only recent FDA actions are routine supplemental labeling updates (2025-06-17 and 2026-03-24), so the defining approval catalyst long ago passed; as an approved drug inside a ~$260/share mega-cap, it scores 3.
Actionable Insight NEUTRAL

XARELTO is a mature cash-flow product, not a share-price driver: historical 1-day stock moves around its FDA approvals were -0.61%, -0.34% and +1.17%, and J&J's 2026-08-17 close was $262.37 with a ~$600B+ market cap. Watch instead for (a) pace of generic rivaroxaban erosion, FDA safety-labeling updates for generic ANDAs from Sun Pharma, Micro Labs and NorthStar Rx confirm generics are already on the U.S. market, and (b) the revived TCPA fax class action against J&J over Xarelto's CarePath program, which the Third Circuit sent back to district court in August 2026.

Price Chart

Loading chart...

Executive Summary

XARELTO (generic: rivaroxaban) is Johnson & Johnson's long-approved oral anticoagulant, manufactured and marketed in the U.S. by its Janssen Pharmaceuticals subsidiary and co-developed with Bayer. It has been on the market since 2011 (tablets; original approvals recorded 2011-07-01 and 2011-11-04) with an oral-suspension form approved 2021-12-20, and its only recent FDA activity is routine labeling upkeep (June 2025 and March 2026 supplements). The product is no longer a growth binary for J&J: generic rivaroxaban tablets from multiple manufacturers (Sun Pharma, Micro Labs, NorthStar Rx) are on the U.S. market, and historical stock moves around XARELTO approvals were under ~1.5% for this diversified mega-cap. J&J also faces residual Xarelto litigation, a product-liability case was dismissed in J&J's favor (May 2026), but a TCPA class action over Xarelto affordability-program faxes was revived by the Third Circuit (August 2026).

How It Works

A pill that thins the blood by blocking Factor Xa, one of the clotting proteins the body uses to form blood clots. It is approved to prevent and treat dangerous blood clots (deep-vein thrombosis, pulmonary embolism) and to reduce stroke risk in patients with an irregular heart rhythm (atrial fibrillation), among other indications. FDA data classifies it as a "Factor Xa Inhibitor."

Trial Status

No pivotal trials pending. FDA records show only supplemental labeling approvals: original XARELTO tablet approvals in 2011, oral suspension NDA 215859 approved 2021-12-20, and labeling supplements approved 2025-06-17 and 2026-03-24. The one local Phase 3 record touching rivaroxaban (NCT03630055, a Canadian investigator-initiated radial-artery occlusion study, mapped to Dr. Reddy's/RDY) was terminated.

The Two-Sided Case

▲ Bull Case4
Established, broadly used anticoagulant franchise: original approvals date to 2011 and the oral-suspension form (NDA 215859) was approved 2021-12-20, with J&J continuing to keep labeling current (supplements approved 2025-06-17 and 2026-03-24).
Legal wins on the product-liability front: the Ninth Circuit affirmed dismissal of a Xarelto case against Janssen and Bayer (May 2026, assessed impact 1/10).
XARELTO is a tiny part of a diversified mega-cap: J&J closed at $262.37 (2026-08-17) with analyst consensus Buy (15 buy + 7 strong-buy, 9 hold, 0 sell) and mean price target $272.50, so the drug's erosion poses limited downside to the stock.
The 2021 suspension approval gave J&J an updated dosage form; historical 1-day stock moves around XARELTO approval catalysts were positive in one case (+1.17% on 2011-07-01).
▼ Bear Case4
Generic erosion is real and underway: FDA records show generic rivaroxaban safety-labeling updates in 2026 for Sun Pharma (ANDA208557), Micro Labs (ANDA208334) and NorthStar Rx (ANDA213114), confirming U.S. generics that undercut the brand's pricing power.
No binary upside left: XARELTO's defining approvals (2011, 2021) already passed, and the remaining FDA actions are routine label changes, nothing that moves a $600B+ company's shares.
Litigation tail-risk: the Third Circuit (Aug 2026) reversed dismissal of a TCPA class action over Xarelto CarePath faxes, reviving a claim with statutory damages of $500-$1,500 per unsolicited fax (assessed bearish, impact 4/10).
Insiders selling: J&J CEO Joaquin Duato exercised options and sold ~$26.7M + ~$5.5M of stock on 2026-08-13 (Form 4 filings), typical of a mature company but a bearish-tinted data point.

Upcoming Catalysts

  • Routine FDA labeling supplements for XARELTO (last two: June 2025 and March 2026), no dated PDUFA or pivotal readout is scheduled in the next ~12 months.
  • TCPA class action against J&J over Xarelto CarePath faxes remanded to district court by the Third Circuit (Aug 2026), procedural progress, not a damages award.
  • J&J quarterly earnings (10-Q filed 2026-07-23; next earnings ~mid-October 2026) where the Innovative Medicine segment discloses Xarelto sales trends amid generic competition.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 6

Hover a chip for the title
1 accessdata.fda.gov2 accessdata.fda.gov3 accessdata.fda.gov4 accessdata.fda.gov5 sec.gov6 sec.gov